U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H18N6O
Molecular Weight 382.4179
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ASP-2535

SMILES

CC(C)C1=NN=C(N1C2=CC=CC3=NON=C23)C4=CC=C(N=C4)C5=CC=CC=C5

InChI

InChIKey=FQGLDGKVKDPVLO-UHFFFAOYSA-N
InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3

HIDE SMILES / InChI

Molecular Formula C22H18N6O
Molecular Weight 382.4179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

ASP-2535 is a glycine transporter-1 (GlyT1) inhibitor which was developed by Astellas Pharma for the treatment of Schizophrenia and Alzheimer's disease. Although ASP-2535 was shown to improve cognitive impairment in animal models, it is no longer in the company pipeline.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
92.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
2012 Jun 15
Patents

Patents

Sample Use Guides

Rats were given ASP-2535 at a dose of 0.1-3 mg/kg
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:40:29 GMT 2023
Edited
by admin
on Sat Dec 16 11:40:29 GMT 2023
Record UNII
6627LI8F9K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASP-2535
Common Name English
2,1,3-BENZOXADIAZOLE, 4-(3-(1-METHYLETHYL)-5-(6-PHENYL-3-PYRIDINYL)-4H-1,2,4-TRIAZOL-4-YL)-
Systematic Name English
4-(3-(1-METHYLETHYL)-5-(6-PHENYL-3-PYRIDINYL)-4H-1,2,4-TRIAZOL-4-YL)-2,1,3-BENZOXADIAZOLE
Systematic Name English
Code System Code Type Description
PUBCHEM
9800113
Created by admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
PRIMARY
FDA UNII
6627LI8F9K
Created by admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
PRIMARY
CAS
374886-51-8
Created by admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
ASP-2535
Created by admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
PRIMARY ASP 2535: Cat. No. 5308Biological Activity: Potent and selective GlyT1 inhibitor (IC50 = 92 nM). Exhibits 50-fold selectivity over GlyT2. Attenuates MK 801-induced working memory deficits and PCP-induced visual learning deficits in mice. Orally available and brain penetrant.
SMS_ID
300000042369
Created by admin on Sat Dec 16 11:40:29 GMT 2023 , Edited by admin on Sat Dec 16 11:40:29 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Originator: Astellas Pharma; Class: Antidementia, Antipsychotic; Highest Development Phases: Discontinued for Alzheimer's disease, Schizophrenia; Most Recent Events: 29 May 2009 Discontinued - Phase-I for Schizophrenia in Japan (PO), 29 May 2009 Discontinued - Phase-I for Alzheimer's disease in Japan (PO), 29 Aug 2008 Phase-I clinical trials in Schizophrenia in Japan (PO)